Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GGJ
|
|||
| Former ID |
DCL000285
|
|||
| Drug Name |
CVT-124
|
|||
| Synonyms |
Adentri; Naxifylline; ENX cpd; BG 9719; BG9719; CVT 124; BG-9719; 1,3-ENX; 1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine; 8-((2S,5,6-Exo)-5,6-epoxy-2-norbonyl)-1,3-dipropylxanthine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Discontinued in Phase 3 | [1] | |
| Company |
CV Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H24N4O3
|
|||
| Canonical SMILES |
CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3CC4CC3C5C4O5
|
|||
| InChI |
1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10+,11+,13-,14+/m1/s1
|
|||
| InChIKey |
OQCJPFYWFGUHIN-GJKBLCTNSA-N
|
|||
| CAS Number |
CAS 166374-49-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| cAMP signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Adenosine P1 receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015498) | |||
| REF 2 | CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009. | |||
| REF 3 | Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc Toxicol. 2003;3(1):71-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.